Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 6, 2010, Pages 1125-1130

  Norris, Robin E ^a   Adamson, Peter C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Aminopterin; Antifol; In vitro; Methotrexate; Pemetrexed; Talotrexin

Indexed keywords

AMINOPTERIN; ANTINEOPLASTIC AGENT; METHOTREXATE; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; PEMETREXED; SULFORHODAMINE B; TALOTREXIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FOLIC ACID ANTAGONIST; GLUTAMIC ACID DERIVATIVE; GUANINE; N(ALPHA) (4 AMINO 4 DEOXYPTEROYL) N(DELTA) HEMIPHTHALOYL L ORNITHINE; N(ALPHA)-(4-AMINO-4-DEOXYPTEROYL)-N(DELTA)-HEMIPHTHALOYL-L-ORNITHINE; ORNITHINE; PTERIN DERIVATIVE;

ACUTE LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LYMPHOMA; PRIORITY JOURNAL; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; LEUKEMIA; LEUKEMIA CELL LINE; PATHOLOGY; TUMOR CELL LINE;

AMINOPTERIN; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; INHIBITORY CONCENTRATION 50; JURKAT CELLS; LEUKEMIA; LYMPHOMA; METHOTREXATE; MOLECULAR STRUCTURE; ORNITHINE; PTERINS;

EID: 77951928817     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1120-8     Document Type: Article

References (34)

1. Adamson PC, Balis FM, Miser J, Arndt C, Wells RJ, Gillespie A, Aronson L, Penta JS, Clendeninn NJ, Poplack DG (1992) Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res 52:521-524
2. Balis FM, Patel R, Luks E, Doherty KM, Holcenberg JS, Tan C, Reaman GH, Belasco J, Ettinger LJ, Zimm S et al (1987) Pediatric phase I trial and pharmacokinetic study of trimetrexate. Cancer Res 47:4973-4976
3. Balis FM, Savitch JL, Bleyer WA (1983) Pharmacokinetics of oral methotrexate in children. Cancer Res 43:2342-2345
4. Burchenal JH, Karnofsky DA, Kingsley-Pillers EM, Southam CM, Myers WP, Escher GC, Craver LF, Dargeon HW, Rhoads CP (1951) The effects of the folic acid antagonists and 2, 6-diaminopurine on neoplastic disease, with special reference to acute leukemia. Cancer 4:549-569
5. Cao S, McGuire JJ, Rustum YM (1999) Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Clin Cancer Res 5:1925-1934
6. Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R (2005) FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10:363-368
7. Cole PD, Drachtman RA, Masterson M, Smith AK, Glod J, Zebala JA, Lisi S, Drapala DA, Kamen BA (2008) Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemother Pharmacol 62:65-75
8. Cole PD, Drachtman RA, Smith AK, Cate S, Larson RA, Hawkins DS, Holcenberg J, Kelly K, Kamen BA (2005) Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res 11:8089-8096
9. Estlin EJ, Pinkerton CR, Lewis IJ, Lashford L, McDowell H, Morland B, Kohler J, Newell DR, Boddy AV, Taylor GA, Price L, Ablett S, Hobson R, Pitsiladis M, Brampton M, Clendeninn N, Johnston A, Pearson AD (2001) A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation. Br J Cancer 84:11-18
10. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 238:787-793
11. Giles F, Rizzieri DA, George S, Stock W, Fontanilla J, Choy GS, Berk GI (2006) A phase I study of Talvesta (R) (Talotrexin) in relapsed or refractory leukemia or myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 108:1968
12. Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R (2005) Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11:982-992
13. Holford NHG (2007) Pharmacokinetics & Pharmacodynamics: rational dosing & the time course of drug action. In: Katzung BG (ed) Basic and Clinical Pharmacology. McGraw-Hill, New York, pp 34-4914.
14. Horton TM, Blaney SM, Langevin AM, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S (2005) Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a Pediatric Oncology Group study. Clin Cancer Res 11:1884-1889 (Pubitemid 40471854)
15. Jackman AL, Taylor GA, Calvert AH, Harrap KR (1984) Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717. Biochem Pharmacol 33:3269-3275
16. Johnson JM, Meiering EM, Wright JE, Pardo J, Rosowsky A, Wagner G (1997) NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase. Biochemistry 36:4399-4411
17. Jonsson OG, Kamen BA (1991) Methotrexate and childhood leukemia. Cancer Invest 9:53-60
18. Kim HM, Han SB, Kim MS, Kang JS, Oh GT, Hong DH (1996) Efficient fixation procedure of human leukemia cells in sulforhodamine B cytotoxicity assay. J Pharmacol Toxicol Methods 36:163-169
19. Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC (2007) Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol 25:1505-1511 (Pubitemid 46759254)
20. Matloub Y, Bostrom BC, Hunger SP, Angiolillo AL, Cole C, Thomson B, Devidas M, Heerema NA, La MK, Buckley PJ, Carroll WL, Winick N, Sather H, Nachman JB, Gaynon PS (2008) Escalating dose intravenous methotrexate without leucovorin rescue during interim maintenance is superior to oral methotrexate for children with standard risk acute lymphoblastic leukemia (SR-ALL) : Children's Oncology Group study 1991. ASH annual meeting abstracts 112:9
21. Messmann RA, Allegra CJ (2001) Antifolates. In: Chabner BA, Longo DL (eds) Cancer Chemotherapy & Biotherapy. Lippincott Williams & Wilkins, Philadephia, pp 139-184
22. Monahan BP, Allegra CJ (2006) Antifolates. In: Chabner BA, Longo DL (eds) Cancer Chemotherapy & Biotherapy: Principles and Practice. Lippincott Williams & Wilkins, Philadelphia, pp 91-124
23. Oettgen HF, Burkitt D, Burchenal JH (1963) Malignant lymphoma involving the jaw in African children: treatment with methotrexate. Cancer 16:616-623
24. Ratliff AF, Wilson J, Hum M, Marling-Cason M, Rose K, Winick N, Kamen BA (1998) Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. J Clin Oncol 16:1458-1464
25. Rosowsky A, Bader H, Cucchi CA, Moran RG, Kohler W, Freisheim JH (1988) Methotrexate analogues. 33. N delta-acyl-N alpha-(4-amino-4-deoxypteroyl)-L- ornithine derivatives: synthesis and in vitro antitumor activity. J Med Chem 31:1332-1337
26. Rosowsky A, Bader H, Wright JE, Keyomarsi K, Matherly LH (1994) Synthesis and biological activity of N-omega-hemiphthaloyl-alpha, omega-diaminoalkanoic acid analogues of aminopterin and 30, 5-dichloroaminopterin. J Med Chem 37:2167-2174 (Pubitemid 24228444)
27. Rosowsky A, Forsch RA, Wright JE (2004) Synthesis and in vitro antifolate activity of rotationally restricted aminopterin and methotrexate analogues. J Med Chem 47:6958-6963
28. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2, 3-d]pyrimidine-based antifolate that inhibits multiple folaterequiring enzymes. Cancer Res 57:1116-1123
29. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM (1998) Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 38:135-152
30. Skeel RT, Cashmore AR, Sawicki WL, Bertino JR (1976) Clinical and pharmacological evaluation of triazinate in humans. Cancer Res 36:48-54
31. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
32. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M, Moran RG (1992) A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3, 4-dihydro-4-oxo-7H-pyrrolo[2, 3-d]pyrimidin-5-yl) ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35:4450-4454
33. Tickoo V, Dey E (2007) UPDATE 2-Hana product development faces setback; shares tank. http://www.reuters.com. Thomson Reuters, Bangalore
34. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM et al (1995) Carrier-and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 48:459-471